ADMA Biologics Inc (ADMA)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 103,147 | 86,707 | 88,244 | 45,325 | 51,352 | 74,157 | 62,513 | 69,204 | 86,522 | 34,906 | 52,415 | 69,505 | 51,089 | 34,411 | 42,409 | 61,966 | 55,921 | 59,675 | 75,781 | 101,236 |
| Short-term investments | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables | US$ in thousands | 49,999 | 50,140 | 30,113 | 49,600 | 27,421 | 31,319 | 36,732 | 26,518 | 15,505 | 20,902 | 18,884 | 25,630 | 28,577 | 20,393 | 23,545 | 15,362 | 13,237 | 6,335 | 6,514 | 7,108 |
| Total current liabilities | US$ in thousands | 55,542 | 44,891 | 44,177 | 53,088 | 49,806 | 41,841 | 41,952 | 36,728 | 39,267 | 44,440 | 28,072 | 31,567 | 30,378 | 32,337 | 18,186 | 21,206 | 19,947 | 16,474 | 12,880 | 13,908 |
| Quick ratio | 2.76 | 3.05 | 2.68 | 1.79 | 1.58 | 2.52 | 2.37 | 2.61 | 2.60 | 1.26 | 2.54 | 3.01 | 2.62 | 1.69 | 3.63 | 3.65 | 3.47 | 4.01 | 6.39 | 7.79 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($103,147K
+ $—K
+ $49,999K)
÷ $55,542K
= 2.76
The quick ratio of ADMA Biologics Inc has shown fluctuations over the periods reported. The quick ratio is a measure of a company's ability to cover its short-term liabilities with its most liquid assets.
From March 31, 2020, to June 30, 2020, the quick ratio decreased from 7.79 to 6.39, indicating a slight decrease in the company's ability to cover its short-term obligations with its quick assets. The ratio continued to decline to 4.01 by September 30, 2020, and further to 3.47 by December 31, 2020.
There was a slight improvement in the quick ratio to 3.65 by March 31, 2021, followed by relatively stable ratios around the 3.5 to 3.7 range until September 30, 2021, when it declined significantly to 1.69. This decrease may raise concerns about the company's liquidity position and its ability to meet short-term obligations.
The quick ratio improved to 2.62 by December 31, 2021, and further increased to 3.01 by March 31, 2022. However, the ratio dropped again to 2.54 by June 30, 2022, and continued to fluctuate in the range of 1.26 to 3.05 over the subsequent quarters.
As of December 31, 2024, the quick ratio stood at 2.76, indicating that the company's liquidity position has improved compared to some previous periods but is still relatively volatile. It is important for stakeholders to monitor the quick ratio closely to assess ADMA Biologics Inc's ability to meet its short-term obligations using its liquid assets.
Peer comparison
Dec 31, 2024